Meanwhile, beta-blockers, mineralocorticoid receptor antagonists (MRA), inhibitors of the renin–angiotensin–aldosterone system, calcium-channel blockers and sodium-glucose cotransporter-2 (SGLT2) inhibitors were equally prescribed in AHF group and control group, given the fact that they are also indicated in chronic heart failure. This evidence concerns the gene NR3C2 and congestive heart failure.